The building of a new, four-story laboratory facility will allow the company, which employs over 500 people in Ireland, to expand its production capacity for presently approved medications and make space for future expansion.

BioMarin creates and markets tailored treatments that deal with the underlying causes of hereditary disorders. It has a production facility in Shanbally and a commercial office in Dublin as part of its Irish operations.

With end-to-end production capabilities, BioMarin's Shanbally facility is its only manufacturing location outside of the United States. It can produce medications from bulk drug ingredient to drug product to final packaging. In 2012, it made its debut.

Following the opening of an aseptic manufacturing facility last year—a four-year construction project that allowed for greater production of commercial and clinical products—this is the site's second major expansion.

"This investment in our Cork facility reflects our ongoing commitment to enhancing our industry-leading global manufacturing capabilities and supporting the growth of our innovative medicines for our people living with rare conditions around the world," said senior vice president and chief quality officer Evelyn Marchany Garcia of BioMarin Pharmaceutical.

"The Shanbally facility plays a crucial role in our global network, and this expansion emphasises our confidence in Ireland's skilled workforce and the strategic importance of this site to BioMarin’s long-term success," it stated.